US EditionJ&J to buy neurological drugmaker Intra-Cellular for $14.6 billion
- Johnson & Johnson has agreed to acquire Intra-Cellular Therapies for $132 per share, totaling about $14.6 billion, marking the largest biotechnology acquisition since early 2023.
- The deal includes Intra-Cellular's drug Caplyta, approved for schizophrenia and bipolar depression, with potential for expanded use in major depressive disorder.
- J&J CEO Joaquin Duato stated the acquisition supports the company's legacy in neuroscience and commitment to advancing care for neuropsychiatric disorders.
- Analysts view the acquisition as a strategic move for J&J, providing opportunities in the neuroscience market despite recent drug failures by competitors.
53 Articles
53 Articles
MedCity News
DealbreakerJ&J Bolsters Its Prospects in Brain Health With $14B Buyout of Intra-Cellular Therapies
Johnson & Johnson’s agreement to acquire Intra-Cellular Therapies brings Caplyta, which is projected to become a blockbuster seller across several neurological indications. In other M&A news, GSK and Eli Lilly each struck deals to fill their cancer drug pipelines. The post J&J Bolsters Its Prospects in Brain Health With $14B Buyout of Intra-Cellular Therapies appeared first on MedCity News.
Associated Press News
Yeshiva World NewsJ&J buys Intra-Cellular in $14.6 billion deal, delving further into central nervous system disorders
Johnson & Johnson will spend more than $14 billion to move deeper into treating central nervous system disorders by purchasing Intra-Cellular Therapies.
J&J Digs Deep In Neuropsych With A $14.6 Billion Acquisition
Johnson & Johnson kicked off the J.P. Morgan Healthcare Conference on Monday with the $14.6 billion acquisition of Intra-Cellular Therapies. The post Johnson & Johnson Buys Intra-Cellular Therapeutics In A Whopping $14.6 Billion Deal appeared first on Investor's Business Daily.
Coverage Details
Bias Distribution
- 55% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
